ERC Starting Grant · 2025
Hypertrophic cardiomyopathy (HCM) is the most common form of cardiomyopathy, affecting 1 in 500 individuals globally. When HCM presents in childhood, adolescence, or early adulthood (0-30yo), it carries a high risk of morbidity and mortality, threatening young lives. Notably, HCM is a leading cause of sudden cardiac death (SCD) in adolescents and young adults without prior warning – a devastating condition affecting over 8000 European youths per year. Despite genetic advances, this knowledge has yet to prevent HCM progression or major complications like arrhythmias, stroke, heart failure, or SCD. Early prediction of adverse outcomes is crucial to identify patients who may benefit from…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.